// App-Quantinova.ai

: The effect of baseline factors on treatment response with MK-7264, a P2X3 antagonist, in refractory chronic cough.

Researchers

Presenter

  • Jaclyn Smith

Principal Investigators

  • Lorcan P Mcgarvey

  • Alyn H. Morice

  • Surinder S Birring

  • Michael M Kitt

  • Mandel R Sher

  • Andrew M Tershakovec

  • Wen-Chi Wu

  • Zhi Jin Xu

  • David R Muccino

Medical Centers

  • University of Manchester, Manchester, United Kingdom

  • Centre for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom

  • The Hull York Medical School, Cottingham, United Kingdom

  • School of Basic and Biomedical Sciences, King's College London, London, United Kingdom

  • Merck & Co., Inc., Kenilworth, NJ, United States,

  • Center for Cough, Largo, Largo, FL, United States of America

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Gefapixant

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Parallel Group

Phase

  • NA

Study Id's

  • NCT02612610

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved